by TractManager | Nov 29, 2022 | Emerging Technology Report
Blarcamesine (ANAVEX 2-73) is an investigational oral drug that targets sigma-1 and muscarinic receptors. It is in development for the treatment of Rett syndrome as well as for a number of other central nervous system disorders.If you have a Hayes login, click here to...
by TractManager | Nov 29, 2022 | Emerging Technology Report
Etranacogene dezaparvovec (Hemgenix; formerly AMT-061) is an adeno-associated virus vector-based gene therapy indicated for the treatment of adults with hemophilia B (congenital factor IX deficiency) who currently use factor IX prophylaxis therapy, have current or...
by TractManager | Nov 23, 2022 | Emerging Technology Report
The Flowsense device is a wireless, noninvasive thermal flow sensor in development for the detection of flow in implanted cerebrospinal fluid shunts in patients with hydrocephalus.If you have a Hayes login, click here to view the full report on the Knowledge...
by TractManager | Nov 22, 2022 | Health Technology Assessment
Focus of the Report: This Health Technology Assessment (HTA) focuses on high-intensity focused ultrasound (HIFU) for primary treatment of localized prostate cancer (PCa).Technology Description: HIFU is a minimally invasive treatment that ablates malignant prostatic...
by TractManager | Nov 21, 2022 | Emerging Technology Report
Teplizumab is an intravenously administered anti-CD3 monoclonal antibody indicated to delay the onset of stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with stage 2 T1D. If you have a Hayes login, click here to view the full...
Recent Comments